Literature DB >> 23829765

Targeted delivery of antisense oligonucleotides by chemically self-assembled nanostructures.

Amit Gangar1, Adrian Fegan, Sidath C Kumarapperuma, Peter Huynh, Alexey Benyumov, Carston R Wagner.   

Abstract

Synthetic nucleic acids have shown great potential in the treatment of various diseases. Nevertheless, the selective delivery to a target tissue has proved challenging. The coupling of nucleic acids to targeting peptides, proteins, and antibodies has been explored as an approach for their selective tissue delivery. Nevertheless, the preparation of covalently coupled peptides and proteins that can also undergo intracellular release as well as deliver more than one copy of the nucleic acid has proved challenging. Recently, we have developed a novel method for the rapid noncovalent conjugation of nucleic acids to targeting single chain antibodies (scFv) using chemically self-assembled nanostructures (CSANs). CSANs have been prepared by the self-assembly of two dihydrofolate reductase molecules (DHFR(2)) and a targeting scFv in the presence of bis-methotrexate (bis-MTX). The valency of the nanorings can be tuned from one to eight subunits, depending on the length and composition of the linker between the dihydrofolate reductase molecules. To explore their potential for the therapeutic delivery of nucleic acids as well as the ability to expand the capabilities of CSANs by incorporating smaller cyclic targeting peptides, we prepared DHFR(2) proteins fused through a flexible peptide linker to cyclic-RGD, which targets αvβ3 integrins, and a bis-MTX chemical dimerizer linked to an antisense oligonucleotide (bis-MTX-ASO) that has been shown to silence expression of eukaryotic translation initiation factor 4E (eIF4E). Monomeric and multimeric cRGD-CSANs were then prepared with bis-MTX-ASO and shown to undergo endocytosis in the breast cancer cell line, MDA-MB-231, which overexpresses αvβ3. The bis-MTX-ASO was shown to undergo endosomal escape resulting in the knock down of eIF4E with at least the same efficiency as ASO delivered by oligofectamine. The modularity, flexibility, and common method of conjugation may prove to be a useful general approach for the targeted delivery of ASOs, as well as other nucleic acids to cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23829765      PMCID: PMC5568898          DOI: 10.1021/mp400164f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  27 in total

Review 1.  Integrins as therapeutic targets.

Authors:  Simon L Goodman; Martin Picard
Journal:  Trends Pharmacol Sci       Date:  2012-05-25       Impact factor: 14.819

2.  Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Authors:  Qing Li; Christopher R So; Adrian Fegan; Vivian Cody; Mehmet Sarikaya; Daniel A Vallera; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2010-11-15       Impact factor: 15.419

3.  Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.

Authors:  Md Rowshon Alam; Xin Ming; Michael Fisher; Jeremy G Lackey; Kallanthottathil G Rajeev; Muthiah Manoharan; Rudy L Juliano
Journal:  Bioconjug Chem       Date:  2011-07-20       Impact factor: 4.774

Review 4.  siRNA conjugate delivery systems.

Authors:  Ji Hoon Jeong; Hyejung Mok; Yu-Kyoung Oh; Tae Gwan Park
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

Review 5.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

Authors:  C Frank Bennett; Eric E Swayze
Journal:  Annu Rev Pharmacol Toxicol       Date:  2010       Impact factor: 13.820

Review 6.  Radiolabelled RGD peptides for imaging and therapy.

Authors:  F C Gaertner; H Kessler; H-J Wester; M Schwaiger; A J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

7.  4E-BP3, a new member of the eukaryotic initiation factor 4E-binding protein family.

Authors:  F Poulin; A C Gingras; H Olsen; S Chevalier; N Sonenberg
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

8.  Translation initiation factor eIF4E is a target for tumor cell radiosensitization.

Authors:  Thomas J Hayman; Eli S Williams; Muhammad Jamal; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Cancer Res       Date:  2012-03-07       Impact factor: 12.701

9.  Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Authors:  Andrew C Hsieh; Davide Ruggero
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

10.  Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α(v)β(3)-Targeted Radiotracer( 99m)Tc-3P-RGD(2).

Authors:  Yang Zhou; Guoqiang Shao; Shuang Liu
Journal:  Theranostics       Date:  2012-06-05       Impact factor: 11.556

View more
  1 in total

1.  In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures.

Authors:  Rachit Shah; Jacob Petersburg; Amit C Gangar; Adrian Fegan; Carston R Wagner; Sidath C Kumarapperuma
Journal:  Mol Pharm       Date:  2016-03-29       Impact factor: 4.939

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.